Sanjay Shukla: And I’ll just reiterate, we’re still retaining that value for 2810. So any IP that’s the other reason, we talked a little bit about. We had some patent language in this script. We’re still retaining that value of any data that’s also coming out of these potential collaborations. So I think it’s a really smart way for us to move things forward in the hands of experts, spend less cash ourselves, but still retain that upside should we see signals in those neuroendocrine phenotypes.
Sean Kim: Okay. Very helpful. Thank you very much.
Operator: One moment. And our last question will come from Kumar Raja of Roth. Your line is open.
Kumaraguru Raja: Thanks for taking my questions. So with regard to the clinical trial side from the Phase 2 trial, what are you seeing in terms of those sites coming onboard in the Phase 3 trial? And also you talked a little bit about the side effect profile. So what are your expectations in terms of the dropout rate here in the Phase 3 trials? Thank you.
Sanjay Shukla: So the trials — thanks Kumar for the question. For the trials sites that were previously involved, we are seeing obviously good uptake initiation, many of these were all centers in the U.S. and those that were involved previously obviously are very, very excited about participating in the next trial. If you look at our CHEST publication, you can look at each of those investigators on that publication. All of those sites are going to be what I would consider our lead sites. And some of these are bulky academic institutions, but even some of the timelines of approval has been rather quick in my estimation on how quickly we’re moving things forward. That’s because we have good data. That’s because we have the data that we can talk about.
And those local ethics and IRB committees, I think our team is doing a really, really good job, but I also have to tip my hat to those institutions that they are also responding quickly because they want to get patients into this trial. And I know many of these centers are also prioritizing our study over even any other sarcoidosis smaller trials that are out there, early phase trials. They realize a late phase trial like this is really, really important. So I think that’s key. You also asked the question about dropout. With 264, the estimation we have here and what we built into the power calculations is seven to eight patients per arm if we have that kind of cushion. So I want to be at 240 patients. So the worst case scenario here is 24 patients or so, eight per arm and then that would actually not impact the power calculations as long as we stay within that.
And other than reasons outside of our control, sometimes there’s some operational reasons. We do not expect anyone necessarily to need to drop out, to go back to say standard of care because that’s written into our protocol. So folks are not doing well, they can go back up on their steroids. In fact, we want that to happen because we think that’s going to happen at a much, much more greater rate in the placebo population. So nonetheless, we still have a cushion as I said, seven to eight patients per arm for dropouts.
Kumaraguru Raja: Very helpful. Thank you so much.
Sanjay Shukla: Sure.
Operator: And I’m showing no further questions. I would now like to hand the call to Sanjay for closing remarks.
Sanjay Shukla: Well, I want to thank everybody. Great questions today. Lots of questions. We appreciate it. Really staying obviously laser focused here on the EFZO-FIT trial. Appreciate a lot of updates today, some strategic decisions that we’ve made. Look forward to interacting in the near future and we really thank everyone’s support listing on the line here our investors. Thank you so much.
Operator: Ladies and gentlemen, this concludes today’s conference. Thank you for your participation. You may now disconnect.
